Oncolytics Biotech (NASDAQ:ONCY) Director Wayne Pisano Buys 30,000 Shares of Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) Director Wayne Pisano bought 30,000 shares of the business’s stock in a transaction dated Thursday, February 12th. The shares were acquired at an average cost of $0.84 per share, with a total value of $25,200.00. Following the completion of the purchase, the director owned 492,414 shares in the company, valued at approximately $413,627.76. This represents a 6.49% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Oncolytics Biotech Price Performance

Oncolytics Biotech stock opened at $1.06 on Friday. The stock’s 50 day moving average price is $0.98 and its 200 day moving average price is $1.07. Oncolytics Biotech Inc. has a 1-year low of $0.33 and a 1-year high of $1.51. The company has a market cap of $112.52 million, a PE ratio of -3.79 and a beta of 0.99.

Oncolytics Biotech (NASDAQ:ONCY) last released its earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. On average, equities research analysts anticipate that Oncolytics Biotech Inc. will post -0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Oncolytics Biotech

Institutional investors and hedge funds have recently bought and sold shares of the stock. Security National Bank of Sioux City Iowa IA acquired a new stake in Oncolytics Biotech during the 4th quarter valued at $29,000. Tocqueville Asset Management L.P. purchased a new stake in shares of Oncolytics Biotech in the fourth quarter valued at $63,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Oncolytics Biotech during the fourth quarter valued at $44,000. Ground Swell Capital LLC purchased a new stake in Oncolytics Biotech during the 4th quarter worth about $30,000. Finally, Scientech Research LLC purchased a new stake in Oncolytics Biotech during the 3rd quarter worth about $25,000. Hedge funds and other institutional investors own 6.82% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ONCY. Weiss Ratings restated a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Monday, December 29th. HC Wainwright upped their price target on Oncolytics Biotech from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, November 17th. Wall Street Zen downgraded Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Finally, Zacks Research upgraded Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Oncolytics Biotech presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.25.

Trending Headlines about Oncolytics Biotech

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: Director Patricia S. Andrews bought 35,400 shares at $0.86 (raising her stake 82.85% to 78,128 shares). SEC Filing
• Positive Sentiment: Insider Andrew Aromando purchased 29,600 shares at $0.86 (increasing his position 116.08% to 55,100 shares). SEC Filing
• Positive Sentiment: Director Bernd R. Seizinger acquired a total of 100,000 shares across Feb. 11–12 (60k at $0.83 and 40k at $0.85), boosting his holdings to ~566,991 shares. SEC Filing
• Positive Sentiment: VP Allison Hagerman bought 10,000 shares at $0.83 (raising her stake ~9.5% to 115,059 shares). SEC Filing
• Positive Sentiment: Director Deborah M. Brown purchased 25,000 shares at $0.85 (a ~29.5% increase; now ~109,851 shares). SEC Filing
• Positive Sentiment: Insider Thomas C. Heineman bought 12,132 shares at $0.83 (increasing to ~282,818 shares). SEC Filing
• Positive Sentiment: Director Wayne Pisano purchased 30,000 shares at $0.84 (raising his stake ~6.5% to ~492,414 shares). SEC Filing
• Positive Sentiment: CFO Kirk Look bought 12,000 shares at $0.84 (increasing to ~287,515 shares). SEC Filing
• Positive Sentiment: CEO Jared Kelly purchased a total of 35,100 shares across Feb. 11–12 at ~$0.84 (bringing his holdings to ~109,000 shares, a ~37% increase). SEC Filing

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.